Urinary Incontinence, Stress Clinical Trial
Official title:
A Randomized Controlled Trial of a Group-Based Therapeutic Yoga Intervention for Urinary Incontinence in Ambulatory Older Women
Verified date | September 2023 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators will conduct a randomized controlled trial to evaluate the efficacy of a group-based yoga intervention to decrease the frequency and impact of urinary incontinence in ambulatory middle-aged and older women and explore potential mediators of improvement in outcomes. Women aged 45 years and older who report daily or more frequent stress-, urgency-, or mixed-type incontinence, are not already engaged in formal yoga or muscle stretching/strengthening programs, are willing to temporarily forgo other clinical treatments for incontinence, are able to walk to and use the bathroom without assistance, and meet other eligibility criteria will be recruited from multiple locations surrounding the San Francisco Bay area.
Status | Completed |
Enrollment | 240 |
Est. completion date | December 31, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 45 Years and older |
Eligibility | Inclusion Criteria: - Women aged 45 years or older who report urinary incontinence starting at least 3 months prior to screening - Self-report an average of at least one incontinence episode per day on a validated voiding diary - Self-report urgency-predominant (i.e., at least half of incontinence episodes being urgency-type), stress-predominant (i.e., at least half of episodes being stress-type), or mixed-type (i.e., an equal number of stress- and urgency-type episodes) incontinence on the screening voiding diary - Willing to refrain from initiating medical treatments that may affect their incontinence or voiding pattern during the study intervention period Exclusion Criteria: - Current participation in organized yoga classes or workshops, or any prior organized yoga training directed specifically at improving incontinence - Current participation in organized physical conditioning classes involving muscle strengthening exercises (e.g., Pilates) - Current urinary tract infection or hematuria detected by urinalysis at screening visit (women can re-present after evaluation and treatment through their usual care) - Currently pregnant (by self-report or screening urine pregnancy test), gave birth within the past 3 months, or planning pregnancy during the study period - Report use of medical devices (i.e. pessary) for incontinence within the past month (participants may stop use of device and re-present for study) - Report use of bladder botox, electrostimulation, formal bladder training, or formal pelvic floor exercise training (with certified practitioners) in the past 3 months - Report any history of prior anti-incontinence or urethral surgery (not including urethral dilation), pelvic cancer, or pelvic irradiation - Report other surgery to the pelvis (hysterectomy, oophorectomy, vaginal surgery, bladder surgery, colon surgery) within the past 3 months - Unable to walk 2 blocks on level ground without assistance (functional capacity < 4 metabolic equivalents) - Unable to get up from a supine to a standing position without assistance (assessed during the screening visit) - Report history of interstitial cystitis, bladder or rectal fistula, or congenital defect causing urinary incontinence - Report incontinence caused by a major neurologic conditions such as multiple sclerosis, spinal cord injury, or Parkinson's disease - Report use of medications with strong effects on urination (anticholinergic bladder medications, beta-3 agonists, tricyclic antidepressants, mirabegron, loop diuretics) within the past month - Report starting, stopping, or changing the dose of a medication with the potential to affect anxiety or depression symptoms (i.e., selective serotonin reuptake inhibitors, anxiolytics/sedatives, antipsychotics) within the past 1 month, or plans to start, stop, or change to dose of such a medication during the study period - Participation in another research study that involves investigational drugs or devices that could potentially confound the results of this study - Unable to understand study procedures, complete study interviews, or and provide informed consent in English - Report conditions that, in the judgment of the investigators, render potential participants unlikely to follow the protocol, including plans to move, substance abuse, significant psychiatric problems, or dementia |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University | Palo Alto | California |
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Stanford University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Total Urinary Incontinence Episodes | Change was calculated as the followup value minus the baseline value. Values are model-generated Least Square Means for combined 6 and 12 week time points. | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Stress-Type Urinary Incontinence Episodes | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Urgency-Type Urinary Incontinence Episodes | Change was calculated as the follow-up value minus the baseline value. Values are model-generated Least Square Means for combined 6 and 12 week time points | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Incontinence Impact Questionnaire (IIQ) | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range 0-400, Higher score indicates lower quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Urogenital Distress Inventory-6 Score (UDI) | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range 0-100, Higher score indicates lower quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Patient Perception of Bladder Condition (PPBC) | Change was calculated as the follow-up value minus the baseline value. Values are model-generated Least Square Means for combined 6 and 12 week time points Range 1-6, Higher score indicates lower quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range 0-60, Higher score indicates lower quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in State/Trait Anxiety Inventory (STAI)--Trait | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range 20-80, Higher score indicates lower quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Hospital Anxiety & Depression (HADS)--Anxiety Score | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range 0-21, Higher score indicates lower quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Perceived Stress Scale (PSS) Score | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range 0-40, Higher score indicates lower quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in PROMIS Physical Function Short Form 8B, T-Score | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points (Mean 50, Std Dev 10) no widely accepted thresholds have been published. Higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in One-legged Balance Test (Winsorized) | Change was calculated as the followup value minus the baseline value. Change values were Winsorized at the 1st and 99th percentile. Values are model generated Least Square Means for combined 6 and 12 week time points. Higher score indicates better quality of life. | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Chair Stands (in 30 Seconds) | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in 2-Minute Step Test | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Wake After Sleep Onset (Winsorized) | Change was calculated as the follow-up value minus the baseline value. Change values were Winsorized at the 1st and 99th percentile. Values are model generated Least Square Means for combined 6 and 12 week time points.
Higher score indicates lower quality of life. |
Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Total Sleep Time | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points.
Higher score indicates better quality of life. |
Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Score | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points.
Range of 0-21, higher score indicates lower quality of life. |
Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Inactive, Condition Impact on Sexual Quality | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Inactive, Condition Specific Reason for Not Being Active | Change was calculated as the follow-up value minus the baseline value. Values are model-generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Inactive, Global Quality | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Inactive, Partner Related Reasons for Not Being Active | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Active, Assessment of Arousal, Orgasm | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Active, Condition-specific Impact on Sexual Quality | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Active, Condition-specifc Impacts on Activity | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Active Interest, Summary Score | Change was calculated as the follow-up value minus the baseline value. Values are model-generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Active, Assessment of Desire | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Active, Global Quality | Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks | |
Secondary | Change From Baseline in Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR)--Sexually Active Interest, Assessment of Partner Related Impacts (Winsorized) | Change was calculated as the followup value minus the baseline value. Change values were Winsorized at the 1st and 99th percentile. Values are model generated Least Square Means for combined 6 and 12 week time points Range of 0-100, higher score indicates better quality of life | Repeated change from baseline to 6 and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02001714 -
Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
|
N/A | |
Not yet recruiting |
NCT00523068 -
Pharmacological vs Surgical Treatment for Mixed Incontinence
|
Phase 4 | |
Completed |
NCT00904969 -
A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence
|
N/A | |
Completed |
NCT00190827 -
Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)
|
Phase 3 | |
Completed |
NCT00190814 -
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.
|
Phase 3 | |
Terminated |
NCT00247286 -
Weighted Vaginal Cones Versus Biofeedback in the Treatment of Urodynamic Stress Incontinence: a Randomized Trial.
|
Phase 4 | |
Completed |
NCT01959347 -
Combined Treatment for Mixed Incontinence
|
Phase 3 | |
Completed |
NCT00244296 -
To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms
|
Phase 4 | |
Not yet recruiting |
NCT05570071 -
A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.
|
N/A | |
Completed |
NCT02334878 -
Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence
|
Phase 3 | |
Completed |
NCT01382602 -
Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
|
Phase 3 | |
Completed |
NCT03296462 -
Hip External Rotation Physical Therapy Trial
|
N/A | |
Recruiting |
NCT02750878 -
Surgical Consent Process for Trans-obturator Tape Slings.
|
N/A | |
Completed |
NCT02296099 -
Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence
|
Phase 4 | |
Completed |
NCT02599051 -
Transobturator Verus Single Incision Slings
|
N/A | |
Completed |
NCT00138749 -
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
|
Phase 2 | |
Terminated |
NCT03614611 -
Canadian Experience With Contiform Intravaginal Device For The Treatment Of Stress Incontinence
|
N/A | |
Completed |
NCT03722719 -
The Knack on Female Stress Urinary Incontinence
|
N/A | |
Active, not recruiting |
NCT02275728 -
Pelvic Floor Muscle Training With and Without Biofeedback in Women With Stress Urinary Incontinence
|
N/A | |
Terminated |
NCT01358214 -
Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)
|
N/A |